We report on the pharmacological effects of the 20 fold D3 vs. D2 dopamine receptor preferring compound U99194A. It is shown that U99194A increases rat locomotor activity at doses that do not increase release or utilisation of dopamine in the striatum or the nucleus accumbens significantly. The data do not support any direct agonist action of U99194A at dopamine receptors. It is suggested that U99194A can antagonise a population of postsynaptic dopamine receptors involved in the suppression of some aspects of psychomotor activity. These postsynaptic receptors presumably belong to the D3 receptor subtype.
To establish possible functional differences between the dopamine D2 and D3 receptor we investigated the relation between the ability, for a set of nine mixed dopamine D2 and D3 receptor antagonists, to displace N, N-dipropyl-2-amino-5,6-dihydroxy tetralin (DP-5,6-ADTN) from striatal binding sites and the subsequent behavioural consequences in vivo. Dopamine D2 receptor preferring antagonists are powerful displacers of DP-5,6-ADTN from the striatum. Maximal displacement is followed by strong hypomotility. Displacement of the agonist by the D3 preferring antagonist U99194A is only partial and results in synergistic increases in locomotor activity. Superimposing haloperidol upon GBR12909 leads to a synergistic increase in striatal dialysate dopamine concentrations. This effect is absent when combining GBR12909 with the putative D3 antagonist U99194A. These data give support for the hypothesis that the dopamine D3 receptor is functionally relevant at the postsynaptic level. Here, in contrast to the D2 receptor, it is proposed to exert an inhibitory influence on psychomotor functions.
Conformational and molecular mechanics studies of a new series of tricyclic ligands with affinity for either the dopamine D2 receptor or the 5-HT1A receptor, or both, has enabled us to elaborate considerably on previous pharmacophore models for these receptors. The new tricyclic ligands are either angular, 2,3,3a,4,5,9b-hexahydro-1H-benz[e]indole derivatives, or linear, 2,3,3a,4,5,9a-hexahydro-1H-benz[f]indole derivatives; they have either cis or trans ring junctions, and many of the ligands are resolved. In order to have X-ray crystal coordinates for every structural type, two additional crystal structures were determined: 14a, the trans-(+-)-6-hydroxy-3-(n-propyl) angular derivative as the hydrochloride, and (+-)-1,2,2a,3,4,8b-hexahydro-8-methoxy-2-(2-propenyl)-naphth[2,1- b]azetidine hydrochloride (16d). Several recently reported imidazoquinolinones with dopaminergic and serotonergic activities were also used in developing the models as were other known ligands which are conformationally constrained. A new method for determining intrinsic activity at the D2 receptor made consistent and reliable estimates of dopamine agonist, partial agonist, and antagonist activities available. The models explain these activities in terms of the 3-dimensional structural features of the ligands and their probable orientations at the D2 receptor site. They also explain why allyl and propyl analogs of some structures have very different affinities while affinities are quite similar for allyl and propyl analogs of other structures; at both receptors a particular orientation of the amine substituent in the binding site correlates with preference for allyl over propyl derivatives. Suggestions are made for enhancing selectivity at the 5-HT1A receptor or at the dopamine D2 receptor. An angular, cis, (3aR,9bS), 2-propyl, 9-hydroxy, 3-(n-propyl) analog should be selective for the 5-HT1A receptor. A linear, trans, (3aR,9aS), 7-hydroxy, 1-(2-propenyl) analog should be selective for the dopamine D2 receptor, and would be predicted to be an antagonist.
1752'8&7,21 7KH QHXURWUDQVPLWWHU GRSDPLQH SOD\V D FHQWUDO UROH LQ FHQWUDO QHUYRXV V\VWHP &16UHODWHG GLVRUGHUV VXFK DV VFKL]RSKUHQLD DQG 3DUNLQVRQ ¶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± 1HYD 3UHVV %UDQIRUG &RQQHFWLFXW $GGUHVV FRUUHVSRQGHQFH DQG UHSULQW UHTXHVWV WR 6 +DDGVPD6YHQVVRQ 6WUXFWXUDO $QDO\WLF DO 0HGLFLQDO &KHPLVWU\3KDUPDFLD 8SMRKQ,QF+HQULHWWD6W.DODPD]RR0,86 $
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.